Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

PaperCitations, authors & open-access status

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 439 citations, 2018 year and closed oa status.

439
Citations
2018
Year
closed
OA Status

Related on ScholarIQ

Amit M. Oza
Author
Robert L. Coleman
Author
David M. O’Malley
Author
Elizabeth M. Swisher
Author
Cancer Discovery
Journal
PARP inhibition in cancer therapy
Topic
470M+ articles · free account